Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on ALEC stock, giving a Buy rating today.Don't Miss our Black ...

"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Alector (ALEC – Research Report), reducing the price target to $7.00.Don't ...

Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...

Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...

H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Alector (ALEC) to $7 from $35 and keeps a Buy rating on the shares. The company announced that the Phase 2 INVOKE-2 trial, which ...

Investigational simufilam failed to reduce cognitive or functional decline in Alzheimer's disease patients in the ReThink-ALZ ...

Stock futures edged lower on Tuesday as sentiment took a hit after President-elect Donald Trump said he would raise tariffs ...

European shares were lower today. The eurozone's STOXX 600 slipped 0.50%, Germany's DAX fell 0.49% and France's CAC 40 ...

Deal Could End Israel-Hezbollah Conflict That Has Lasted Over a Year Lebanon’s caretaker cabinet is expected to meet to formally approve the deal, in which it would play an essential role. Maps ...

Nov. 13, 2024 — An international team of scientists has identified a surprising factor that accelerates the degradation of lithium-ion batteries leading to a steady loss of charge. This ...

A woman is reflected on an electronic stock quotation board outside a brokerage in Tokyo, Japan, August 6, 2024. REUTERS/Willy Kurniawan/File Photo Asian stocks were heavy on Wednesday as ...